Mindpeak Announces Collaboration With Roche to Enhance Cancer Diagnostics Through AI
Mindpeak Announces Collaboration With Roche to Enhance Cancer Diagnostics Through AI
Mindpeak announces its collaboration with Roche that will integrate Mindpeak's innovative AI algorithm with Roche’s Digital Pathology Open Environment, playing a crucial role in helping clinicans improve patient care and expanding personalized medicine.
In a healthcare landscape where millions of diagnostic tests are performed daily, laboratories have become some of the largest data providers. The rising data volume, combined with the need to perform more tests in less time and at lower costs, presents significant challenges. To help address these demands, Roche’s navify® Digital Pathology enterprise software now seamlessly incorporates Mindpeak’s cutting-edge AI algorithms, offering a solution to reduce pre-analytical errors, enhance workflow efficiency, and track key laboratory KPIs in real-time.
Mindpeak’s integration into navify® Digital Pathologyis designed to improve diagnostic precision and facilitate precision medicine, ultimately leading to better patient care. As part of a comprehensive digital pathology solution, navify® Digital Pathology enables interdepartmental collaboration, allowing structured access to therapy-relevant patient data.
About Mindpeak
Mindpeak is the leading innovator in AI software for pathology. With over 30,000 patients diagnosed with the help of Mindpeak’s AI, and over 20 publications in relevant journals and conferences, Mindpeak is a pioneer in AI solutions for both clinical laboratories and biopharma companies. Mindpeak’s AI algorithms were the first to be employed in digital pathology for routine clinical diagnostics in both the USA and the EU.
For more information, please visit our website: www.mindpeak.ai
Mindpeak GmbH
Katja Eisele
Email: katja.eisele@mindpeak.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20240911559160/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk